PMID- 23806439
OWN - NLM
STAT- MEDLINE
DCOM- 20140508
LR  - 20240318
IS  - 1873-7528 (Electronic)
IS  - 0149-7634 (Print)
IS  - 0149-7634 (Linking)
VI  - 37
IP  - 8
DP  - 2013 Sep
TI  - Exercise as a novel treatment for drug addiction: a neurobiological and 
      stage-dependent hypothesis.
PG  - 1622-44
LID - S0149-7634(13)00166-8 [pii]
LID - 10.1016/j.neubiorev.2013.06.011 [doi]
AB  - Physical activity, and specifically exercise, has been suggested as a potential 
      treatment for drug addiction. In this review, we discuss clinical and preclinical 
      evidence for the efficacy of exercise at different phases of the addiction 
      process. Potential neurobiological mechanisms are also discussed focusing on 
      interactions with dopaminergic and glutamatergic signaling and chromatin 
      remodeling in the reward pathway. While exercise generally produces an 
      efficacious response, certain exercise conditions may be either ineffective or 
      lead to detrimental effects depending on the level/type/timing of exercise 
      exposure, the stage of addiction, the drug involved, and the subject population. 
      During drug use initiation and withdrawal, its efficacy may be related to its 
      ability to facilitate dopaminergic transmission, and once addiction develops, its 
      efficacy may be related to its ability to normalize glutamatergic and 
      dopaminergic signaling and reverse drug-induced changes in chromatin via 
      epigenetic interactions with brain-derived neurotrophic factor (BDNF) in the 
      reward pathway. We conclude with future directions, including the development of 
      exercise-based interventions alone or as an adjunct to other strategies for 
      treating drug addiction.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Lynch, Wendy J
AU  - Lynch WJ
AD  - Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, 
      1670 Discovery Drive, Charlottesville, VA 22911, USA. Electronic address: 
      wlynch@virginia.edu.
FAU - Peterson, Alexis B
AU  - Peterson AB
FAU - Sanchez, Victoria
AU  - Sanchez V
FAU - Abel, Jean
AU  - Abel J
FAU - Smith, Mark A
AU  - Smith MA
LA  - eng
GR  - R01-AA016554/AA/NIAAA NIH HHS/United States
GR  - R01 DA027485/DA/NIDA NIH HHS/United States
GR  - R01-DA024716/DA/NIDA NIH HHS/United States
GR  - R01 DA024716/DA/NIDA NIH HHS/United States
GR  - R01 DA031725/DA/NIDA NIH HHS/United States
GR  - R01-DA024716-S1/DA/NIDA NIH HHS/United States
GR  - R01 AA016554/AA/NIAAA NIH HHS/United States
GR  - R01-DA027485/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20130624
PL  - United States
TA  - Neurosci Biobehav Rev
JT  - Neuroscience and biobehavioral reviews
JID - 7806090
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Brain/metabolism
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Chromatin Assembly and Disassembly/physiology
MH  - Dopamine/metabolism
MH  - Exercise/*physiology
MH  - Exercise Therapy/*methods
MH  - Humans
MH  - Substance-Related Disorders/metabolism/*therapy
PMC - PMC3788047
MID - NIHMS499347
OTO - NOTNLM
OT  - Addiction
OT  - Animal models
OT  - Chromatin
OT  - Clinical
OT  - Dopamine
OT  - Epigenetic
OT  - Exercise
OT  - Glutamate
OT  - Neurobiological mechanisms
EDAT- 2013/06/29 06:00
MHDA- 2014/05/09 06:00
PMCR- 2014/09/01
CRDT- 2013/06/29 06:00
PHST- 2013/03/11 00:00 [received]
PHST- 2013/04/29 00:00 [revised]
PHST- 2013/06/13 00:00 [accepted]
PHST- 2013/06/29 06:00 [entrez]
PHST- 2013/06/29 06:00 [pubmed]
PHST- 2014/05/09 06:00 [medline]
PHST- 2014/09/01 00:00 [pmc-release]
AID - S0149-7634(13)00166-8 [pii]
AID - 10.1016/j.neubiorev.2013.06.011 [doi]
PST - ppublish
SO  - Neurosci Biobehav Rev. 2013 Sep;37(8):1622-44. doi: 
      10.1016/j.neubiorev.2013.06.011. Epub 2013 Jun 24.